Insider Transactions in Q1 2025 at Mineralys Therapeutics, Inc. (MLYS)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 13
2025
|
Samsara Bio Capital Gp, LLC |
BUY
Open market or private purchase
|
Indirect |
600,000
+9.56%
|
$7,800,000
$13.5 P/Share
|
|
Mar 13
2025
|
Srinivas Akkaraju |
BUY
Open market or private purchase
|
Indirect |
600,000
+9.56%
|
$7,800,000
$13.5 P/Share
|
|
Mar 13
2025
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
1,296,296
+23.25%
|
$16,851,848
$13.5 P/Share
|
|
Mar 12
2025
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,349
+3.58%
|
$6,349
$1.08 P/Share
|
|
Feb 12
2025
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,348
+3.72%
|
$6,348
$1.08 P/Share
|
|
Jan 13
2025
|
Jon Congleton Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
18,333
-2.05%
|
$164,997
$9.06 P/Share
|
|
Jan 13
2025
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,367
+3.53%
|
$0
$0.81 P/Share
|
|
Jan 13
2025
|
Adam Scott Levy CFO and Secretary |
SELL
Open market or private sale
|
Direct |
10,757
-2.27%
|
$96,813
$9.36 P/Share
|